Corcept Therapeutics Incorporated - Common Stock (CORT)
70.95
-0.76 (-1.06%)
NASDAQ · Last Trade: Apr 28th, 6:58 PM EDT
Detailed Quote
Previous Close
71.71
Open
73.86
Bid
70.86
Ask
72.20
Day's Range
70.73 - 74.56
52 Week Range
22.60 - 117.33
Volume
1,377,466
Market Cap
8.22B
PE Ratio (TTM)
57.68
EPS (TTM)
1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,638,341
Chart
About Corcept Therapeutics Incorporated - Common Stock (CORT)
Corcept Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for patients with severe metabolic and psychiatric disorders. The company primarily specializes in the modulation of glucocorticoid signaling, a pathway that plays a key role in various diseases, particularly those characterized by chronic stress and inflammation. Corcept's lead product is designed to help patients suffering from conditions such as Cushing's syndrome, and the company is also engaged in research aimed at expanding its therapeutic applications to broader health issues. Through its dedication to advancing scientific understanding and developing effective therapies, Corcept aims to improve the quality of life for patients battling these challenging health conditions. Read More
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.7%. This drawdown was worse than the S&P 500’s 5.2% decline.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that trade tariffs could add upward pressure to inflation in the short term and complicate the Fed's efforts to stabilize the economy.
NASDAQ:CORT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
